By comparing metabolome and gene expression profiles of chemotherapy-sensitive vs. resistant GBM cells, PGE2 has been shown to participate in the development of TMZ resistance via the COX-2 pathway [116]. This evidence concerns the gene PTGS2 and glioblastoma.